Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations

Fig. 2

Dose-response comparison of two different D2C7-IT concentrations in orthotopic glioma models. Treatment schedule, survival curves, and median survival are shown for C57BL/6 J mice bearing intracranial CT-2A-dmEGFRvIII-Luc tumors (a) and VM/Dk mice bearing intracranial SMA560-dmEGFRvIII-Luc tumors (b) infused with either vehicle control, 0.1μg D2C7-IT, or 0.3μg D2C7-IT. The p-values generated from the generalized Wilcoxon test are provided for both tumor models

Back to article page